[Time-influencing factors for biochemical progression following radical prostatectomy]

Actas Urol Esp. 2011 Apr;35(4):201-7. doi: 10.1016/j.acuro.2010.08.008.
[Article in Spanish]

Abstract

Introduction: We assessed the time-influencing clinical-pathological factors for biochemical progression of an equal series of patients from a single institution.

Materials and methods: Retrospective analysis of 278 patients with biochemical progression following prostatectomy. We considered biochemical progression to be PSA>0.4 ng/ml. We performed the trial using the Cox model (univariate and multivariate) and using the Student's t-test to compare averages.

Results: With a mean follow-up of 4 (±3 DE) years, the univariate study showed a mean until progression for the Gleason score 2-6 in the biopsy of 824 days and 543 for the Gleason score 7-10 (p=0.003). For negative surgical margins, the mean was 920 days and 545 for positive margins (p=0.0001). In the case of a Gleason score 2-7 in the specimen, the mean was 806 days and 501 for a Gleason score 8-10 (p=0.001). Lastly, the mean for the cases with Ki-67 negative in the specimen (< 10%) was 649 days and 345 for Ki-67 positive (> 10%) (p=0.003). In the multivariate study, Ki-67 (OR 1.028; IC 95% 1-1.01; p=0.0001) and Gleason score 8-10 (OR 1.62; IC 95% 1.5-2.45; p=0.026) in the specimen, and initial PSA >10 ng/ml (OR 1.02; IC 95% 1.01-1.04; p=0.0001) were independent variables. Using these variables, we designed a predictive model with three groups. The time until the progression of each group was 1,081, 551 and 218 days respectively.

Conclusion: The Gleason score 7-10 in the prostate biopsy, the presence of Ki-67, the positive margins and the Gleason score 8-10 in the specimen, and the initial PSA > 10 ng/ml are time-influencing factors until biochemical progression. Pathological Gleason score 8-10, PSA > 10 ng/ml and Ki-67 are independent factors.

Publication types

  • English Abstract

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / secondary*
  • Adenocarcinoma / surgery
  • Biopsy
  • Disease Progression
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Lymph Node Excision
  • Male
  • Neoplasm Staging
  • Proportional Hazards Models
  • Prostate-Specific Antigen / blood*
  • Prostatectomy* / methods
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery
  • Retrospective Studies
  • Risk Factors
  • Time Factors

Substances

  • Prostate-Specific Antigen